# SAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment Conference

May 12, 2022

SIOUX FALLS, S.D., May 12, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), announced today its participation at the **H.C. Wainwright Global Investment Conference**, which takes place May 23-26, 2022. As part of the conference, the company's management team will participate in a live Fireside Chat on **Wednesday, May 25, 2022 at 9:00 am EDT / 8:00 am CDT.**

An on-demand webcast of the presentation will be accessible under "News & Events" in the Investors section of the company's website at www.sabbiotherapeutics.com. A replay of the webcast will be available on the SAB website for 90 days following the presentation.

*H.C. Wainwright hosted events are intended for prospective and existing H.C. Wainwright clients only. To request a one-on-one meeting with management or to participate at the live event, please contact your H.C. Wainwright representative with interest.*

**About SAB Biotherapeutics, Inc.**
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies with a focus on building a leading immune and autoimmune disorders pipeline. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ that produce fully human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune and autoimmune disorders including type 1 diabetes and organ transplantation, and cancer. SAB's versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB currently has multiple drug development programs underway and collaborations with the US government and global pharmaceutical companies.

For more information on SAB, visit: https://www.sabbiotherapeutics.com and follow @SABBantibody on Twitter.

**Investor Relations Contact:**

Aman R. Patel
+1 (443) 450-4191
aman.patel@westwicke.com